Foresee Pharmaceuticals
Foresee is a Taipei biotech whose long-acting leuprolide depot, Camcevi, is an injection for advanced prostate cancer, and which runs phase 3 trials as lead sponsor.
Overview
Foresee Pharmaceuticals, headquartered in Taipei, Taiwan, developed a ready-to-use six-month leuprolide mesylate depot (Camcevi) for advanced prostate cancer, approved in the United States and Europe, and is developing further hormone and immunology products. It is lead sponsor of several phase 3 trials registered on ClinicalTrials.gov.
Scorecard
All companies- approved products +6
- targets +2
- modalities +2
- regions +6
- registry trials +8
Similar pages
not linked directly; found by shared links- CompanyTolmar
Shares Leuprolide (leuprorelin) and GnRH agonists, Prostate cancer and the tag ctgov-sponsor.
- CompanyBavarian Nordic
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanyFutureChem
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanyHinova Pharmaceuticals
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanySpectraCure
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanySOTIO Biotech
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanyABX advanced biochemical compounds
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanyVeru
Shares Prostate cancer and the tag ctgov-sponsor.